Krystal Biotech announced that it has expanded its R&D pipeline to oncology and that the FDA has accepted its investigational new drug, or IND, application of its lead oncology drug candidate KB707 for the treatment of locally advanced or metastatic solid tumor malignancies. The company will host an investor conference call and webcast, Thursday, July 27 to discuss the KB707 program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech files to sell 1.73M shares of common stock for holders
- Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis
- Krystal Biotech doses first patient in Phase 1 trial of KB407
- Krystal Biotech price target raised to $160 from $130 at TD Cowen
- Krystal Biotech to Present at Upcoming Investor Conferences